Observational studyChest2014
Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis.
Observational study in Chest, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Single-Cell Analysis Identifies Factors Associated with Rheumatoid Arthritis-Related Interstitial Lung Disease in Comparison with Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Radiological Change in Interstitial Lung Abnormalities and Interstitial Lung Disease in Patients With Rheumatoid Arthritis at 1 Year.International journal of rheumatic diseases · 2026Article
- Association between anti-citrullinated peptide antibodies and subclinical interstitial lung disease in community-dwelling adults: the multi-ethnic study of atherosclerosis.Respiratory research · 2026Article
- Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis.Rheumatology (Oxford, England) · 2025Article
- Association between rheumatoid arthritis and interstitial lung disease and impact of serologic status: a large-scale longitudinal study.Scientific reports · 2025Article
- Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.Arthritis care & research · 2025Article
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.Current treatment options in rheumatology · 2024Article
- Multi-Ancestry Causal Association between Rheumatoid Arthritis and Interstitial Lung Disease: A Bidirectional Two-Sample Mendelian Randomization Study.Journal of clinical medicine · 2024Article
- Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicentre prospective cohort of smokers.Rheumatology (Oxford, England) · 2023Article
- Molecular Factors in PAD2 (Cells · 2023Article
- Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis.Rheumatology international · 2023Article
- Pulmonary Hypertension in the Course of Interstitial Lung Diseases-A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy.Diagnostics (Basel, Switzerland) · 2023Review
- Pulmonary Cryptococcosis Diagnosed by a Transbronchial Lung Cryobiopsy in a Patient with Rheumatoid Arthritis.Internal medicine (Tokyo, Japan) · 2023Article
- Interstitial Lung Disease in Primary Biliary Cholangitis: A Cohort Prospective Study.Life (Basel, Switzerland) · 2023Article
- Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study.The Lancet. Rheumatology · 2023Article
- Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease.Frontiers in immunology · 2023Review
- Screening for preclinical parenchymal lung disease in rheumatoid arthritis.Rheumatology (Oxford, England) · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundApproximately 10% of patients with rheumatoid arthritis (RA) have interstitial lung disease (ILD), and one-third have subclinical ILD on chest CT scan. In this study, we aimed to further characterize functional decrements in a spectrum of RA-associated ILD.
methodsAll subjects were enrolled in the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS). The presence of interstitial lung abnormalities (ILAs) on clinically indicated chest CT scans was determined using a previously validated sequential reading method. Univariate and multivariate analyses were used to assess the association between degree of ILAs and physiologic, functional, and demographic variables of interest.
resultsOf 1,145 BRASS subjects, 91 subjects (8%) were included in this study. Twelve had radiologically severe ILAs, 34 had ILAs, and 38 had no ILAs on CT scan. Subjects with radiologically severe ILAs were older (P = .0037), had increased respiratory symptoms (cough, P = .027; dyspnea, P = .010), and more severe RA disease (rheumatoid factor, P = .018; total swollen joints, P = .046) compared with subjects with no ILAs. Participants also had a trend toward having an increased smoking history (P = .16) and having lower FVC % predicted (77% vs 94%, P = .097) and diffusion capacity of carbon monoxide % predicted (52% vs 77%, P = .068). Similar but attenuated increases in respiratory symptoms, functional decrements, and RA disease severity were observed in subjects with ILAs compared with those with no ILAs.
conclusionsWe have shown that patients with RA have varying degrees of ILAs that are associated with a spectrum of functional and physiologic decrements. Our findings suggest that improved risk stratification and detection of ILAs will provide a therapeutic window that could improve RA-ILD outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.